Cytokinetics to Participate in Annual Healthcare Conference
Cytokinetics, a biopharmaceutical company specializing in cardiovascular treatments, announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. Management will present in a fireside chat to discuss updates on its pipeline, including its approved drug MYQORZO®, and engage with the healthcare investment community. A webcast of the presentation will be available on the company’s website for 90 days.
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Cytokinetics, Incorporated (Nasdaq: CYTK) announced that its management team will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 1:30 PM Eastern Time. The specialty cardiovascular biopharmaceutical company will make the live webcast accessible via the Investors & Media section of its website, with a replay available for 90 days. The company is known for its work in muscle biology and advancing a pipeline of new medicines for cardiac muscle dysfunction, including MYQORZO® (aficamten) and investigational treatments like omecamtiv mecarbil and ulacamten.
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Cytokinetics, Incorporated announced its management team will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 1:30 PM Eastern Time. Interested parties can access the live webcast via the Investors & Media section of the company's website, with a replay available for 90 days. Cytokinetics is a biopharmaceutical company focused on developing therapies for cardiac muscle dysfunction, including their approved drug MYQORZO® (aficamten) and investigational candidates omecamtiv mecarbil and ulacamten.
Cytokinetics (CYTK) Is Up 6.8% After MYQORZO FDA Approval Amid Insider Sales And Probe - What's Changed
Cytokinetics recently received FDA approval for MYQORZO (aficamten), a significant milestone for its cardiovascular franchise. While this de-risks the core oHCM thesis, the company faces ongoing shareholder investigations, persistent negative equity, and concerns about pipeline concentration and competition. The article highlights the contrast between regulatory success and internal challenges, emphasizing the need for robust commercialization and governance.
CYTK PE Ratio & Valuation, Is CYTK Overvalued
This article analyzes Cytokinetics Inc (CYTK) valuation, concluding that it is currently undervalued. Based on a relative valuation method, the fair price range for CYTK is estimated to be between $106.38 and $263.57, significantly higher than its current price of $66.73. The article also details various financial metrics like P/B ratio, FCF yield, and P/S ratio, comparing them to historical averages and industry benchmarks.
A Look At Cytokinetics (CYTK) Valuation After MYQORZO FDA Approval And Aficamten Regulatory Updates
Cytokinetics (CYTK) is gaining investor attention following the FDA approval of MYQORZO and upcoming Q4 earnings, alongside regulatory updates for Aficamten. The stock is considered 16.1% undervalued, with a fair value of $79.56, largely based on the potential of aficamten and pipeline execution, despite some remaining risks. The company's strong balance sheet and potential partnerships are expected to support future growth and reduce business risk.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Cytokinetics, Incorporated (NASDAQ:CYTK) on behalf of investors who purchased securities prior to December 27, 2023, and still hold them. The investigation focuses on whether the company's officers or directors engaged in corporate wrongdoing. Shareholders are encouraged to contact the law firm for more information and to assist in the investigation.
CYTK SEC Filings - Cytokinetics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Cytokinetics (CYTK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It highlights recent filings such as a Form 4 detailing an insider stock sale and a Q2-25 10-Q report discussing financial performance, a Bayer deal, and pipeline updates. The platform uses AI-powered tools to summarize these documents and track their impact and sentiment.
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK)
Andrew Callos, Executive Vice President, Chief Commercial Officer at Cytokinetics Inc (CYTK), sold 3,639 shares of the company on March 31, 2026, reducing his total holdings to 66,004 shares. This transaction is part of a pattern of insider selling, with no insider buys and 70 insider sells recorded for CYTK over the past year. The stock was trading at $65, suggesting it might be a "Possible Value Trap" with a price-to-GF-Value ratio of 0.31.
Insider sale: Cytek (NASDAQ: CYTK) files to sell 45,000 RSUs
Robert Blum, an insider at Cytek (NASDAQ: CYTK), filed Form 144 to report the planned disposal of 45,000 Restricted Stock Units (RSUs) and prior sales. The filing details two recent disposals of 36,601 shares for over $2.2 million and 7,931 shares for over $481,000. These transactions are routine disclosures of planned and completed sales under SEC Rule 144.
Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares, retains large stake
Cytokinetics Inc. CEO Robert I. Blum sold 7,500 shares of common stock at $66.63 per share in an open-market transaction. Following this sale, Blum directly holds 422,830 shares and indirectly holds additional shares through two irrevocable trusts. This insider transaction was filed via SEC Form 4.
Evercore ISI reiterates Cytokinetics stock rating ahead of trial data
Evercore ISI has reiterated an Outperform rating and an $80.00 price target for Cytokinetics (NASDAQ:CYTK) due to optimism surrounding the upcoming Phase 3 ACACIA trial results for Myqorzo (aficamten) in non-obstructive hypertrophic cardiomyopathy. The firm anticipates a 65% probability of the trial meeting primary endpoints, which could significantly enhance the drug's market position and value. Several other analysts, including Mizuho, JPMorgan, Stifel, Leerink Partners, and UBS, have also issued positive updates and increased price targets for Cytokinetics, reflecting strong confidence in the company's approved and pipeline assets.
Evercore ISI reiterates Cytokinetics stock rating ahead of trial data
Evercore ISI has reiterated an Outperform rating and an $80 price target for Cytokinetics (NASDAQ:CYTK) as the company approaches the readout of its Phase 3 ACACIA trial. The trial evaluates Myqorzo (aficamten) for non-obstructive hypertrophic cardiomyopathy, with Evercore ISI assigning a 65% probability of hitting primary endpoints. The firm expects the stock to trade significantly higher if the drug's profile proves clinically meaningful, irrespective of which endpoint is met.
CYTK Stock News Today | Earnings, Events & Price Alerts
This page provides a compilation of recent news and events related to Cytokinetics (CYTK) stock, including articles from NASDAQ.COM and Fool.com, discussing stake reductions, executive stock sales, and earnings reports. It also mentions key events and earnings analyses, highlighting the company's financial performance and FDA approvals. The page acts as a centralized source for investors to track CYTK's market activities.
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK)
Andrew Callos, Executive Vice President and Chief Commercial Officer at Cytokinetics Inc (CYTK), sold 3,639 shares of the company on March 31, 2026. This transaction brings his total ownership to 66,004 shares. The article notes a history of insider selling at Cytokinetics Inc with no insider buys in the past year, and suggests the stock may be a "Possible Value Trap" based on its GuruFocus Value.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Cytokinetics, Incorporated (NASDAQ:CYTK). The firm is encouraging shareholders who purchased Cytokinetics securities before December 27, 2023, and still hold them, to contact them for more information and to assist in the investigation. The investigation focuses on potential claims against the company's officers and/or directors.
3,639 RSUs registered; CYTK (NASDAQ: CYTK) insider 10b5-1 sales listed
Cytokinetics (NASDAQ: CYTK) has filed a Form 144 to register the proposed sale of 3,639 Restricted Stock Units (RSUs) dated March 6, 2026. The filing also details multiple pre-arranged 10b5-1 sales by insider Andrew Callos between January 2, 2026, and March 18, 2026, including transactions of 15,000 shares and 11,000 shares on March 5, 2026, with reported proceeds. This indicates routine insider trading activity rather than information-based trading.
Cytokinetics (CYTK) EVP sells 3,639 shares, retains 66,004
Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), sold 3,639 shares of Common Stock at $65.00 per share on March 31, 2026. Following this transaction, Callos directly holds 66,004 shares of Cytokinetics Common Stock. This open-market sale, detailed in a Form 4 filing, amounted to $236,535.
Callos, Cytokinetics EVP, sells $236k in shares
Andrew Callos, EVP and Chief Commercial Officer at Cytokinetics INC, sold 3,639 shares of company stock for a total of $236,535. This transaction occurred near the stock's 52-week high, following a significant 57% return over the past year. Several analyst firms, including Mizuho, JPMorgan, Stifel, Leerink Partners, and UBS, have recently updated their price targets and ratings for Cytokinetics, reflecting varying degrees of optimism about its future prospects.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Cytokinetics, Incorporated (CYTK). The firm is encouraging shareholders who purchased Cytokinetics securities before December 27, 2023, and continue to hold them, to come forward and assist in the investigation. This class-action firm represents investors on a contingency fee basis, aiming to restore investor capital and ensure corporate accountability.
Vanguard disaggregates holdings; CYTK filings now split among subsidiaries (CYTK)
The Vanguard Group filed an amendment (Schedule 13G/A) for Cytokinetics Inc., reporting 0 shares beneficially owned due to an internal realignment. This realignment means certain Vanguard subsidiaries will now report beneficial ownership separately, as per SEC Release No. 34-39538. Investors tracking Cytokinetics ownership should look for separate filings from Vanguard's subsidiaries for relevant holdings.
Why Has Cytokinetics (CYTK) Declined by 0.8% Following Its Most Recent Earnings Announcement?
Cytokinetics (CYTK) shares have dipped by 0.8% recently, despite outperforming the S&P 500. The company reported a wider net loss for Q4 2025 but exceeded revenue expectations, primarily due to non-drug sales and milestone payments. A key development is the FDA approval and upcoming European launch of Myqorzo (aficamten), alongside ongoing clinical trials for other pipeline assets.
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Cytokinetics, Incorporated (NASDAQ:CYTK) and certain officers/directors. The firm is encouraging investors who purchased Cytokinetics securities prior to December 27, 2023, and still hold them, to contact them to learn more and assist in the investigation. The investigation aims to recover investor capital and ensure corporate accountability.
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?
Cytokinetics (CYTK) shares have decreased by 0.8% since its last earnings report, yet outperformed the S&P 500. The company reported a wider-than-expected Q4 2025 net loss of $1.50 per share but revenues of $17.7 million surpassed estimates. Key developments include the FDA approval of Myqorzo (aficamten) and ongoing advancements in its pipeline, especially for heart failure treatments.
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp
DelveInsight's "Spinal Muscular Atrophy Pipeline Insight, 2026" report indicates that over 18 companies are developing more than 20 SMA treatment therapies. The report highlights emerging therapies like SKG 0201, BIIB115, and Apitegromab, and discusses key clinical trial milestones and FDA approvals in late 2025 and early 2026. Significant advancements include new gene therapies and modified treatments showing improved motor function and neuroprotection for SMA patients.
Cytokinetics Inc (HAM:KK3A) Stock Holders - Institutional & Insider Ownership
This article provides an overview of Cytokinetics Inc (HAM:KK3A) stock, focusing on its institutional and insider ownership. It highlights current stock performance data, including market capitalization and P/E ratio, and discusses the importance of institutional and insider ownership percentages for investors. The article also notes GuruFocus's warning signs for KK3A and changes in short interest data availability.
Cautious Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback
Cytokinetics (CYTK) has experienced a recent share price pullback despite strong long-term returns, leading to a valuation discussion. Simply Wall St indicates the stock is 23.4% undervalued with a narrative fair value of $79.56, based on assumptions of aggressive growth and profitability, a strong balance sheet, and potential partnerships. However, the analysis also highlights risks such as regulatory setbacks or slower adoption of their therapies.
E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK
E. Ohman J or Asset Management AB reduced its stake in Cytokinetics (NASDAQ:CYTK) by 10.8% in Q4, now holding 362,962 shares valued at $23.06 million. Despite insiders being net sellers, analysts maintain a "Moderate Buy" rating with an average target price of $89.89 for the biopharmaceutical company. Cytokinetics reported an EPS of ($1.50) for the last quarter, missing estimates, but revenue exceeded expectations.
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Cytokinetics, Incorporated (NASDAQ: CYTK) concerning potential corporate wrongdoing. Shareholders who purchased Cytokinetics securities before December 27, 2023, and still hold them, are encouraged to contact the firm to assist in the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP has increased its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 15.4%, now owning 182,131 shares valued at $10.01 million. This increase in institutional investment, alongside several analyst price target upgrades, signals positive sentiment for the biopharmaceutical company. However, recent significant insider selling by CEO Robert Blum and other executives, totaling nearly $10 million in the past 90 days, could exert short-term pressure on the stock despite the positive analyst outlook.
Cytokinetics (CYTK) EVP sells 1,930 shares, retaining over 78,000
Andrew Callos, Executive Vice President and Chief Commercial Officer at Cytokinetics (CYTK), sold 1,930 shares of common stock in an open-market transaction at $62.07 per share. Following this sale, Callos retains direct ownership of 78,185 shares of Cytokinetics common stock. The transaction was reported in a Form 4 SEC filing, indicating it was executed under a Rule 10b5-1 trading plan.
Cytokinetics gives 5 new hires options, RSUs under Nasdaq rule
Cytokinetics (Nasdaq: CYTK) granted inducement equity awards to five new employees on March 13, 2026, comprising 8,628 stock options and 5,719 Restricted Stock Units (RSUs). These grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment, indicating they are part of a recruitment strategy. The stock options have an exercise price of $60.06 and a 10-year term, while the RSUs will vest over three years, both subject to continued employment.
Cytokinetics (CYTK) CEO executes sell-to-cover stock sales for taxes
Cytokinetics President and CEO Robert I. Blum sold 36,601 common shares at $62.15 each in "sell-to-cover" transactions. These sales were not discretionary but were mandated by the company to meet tax withholding obligations related to restricted stock unit (RSU) vesting. Following these transactions, Blum directly holds 430,330 shares, with additional shares held indirectly through two irrevocable trusts.
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850
Malik Fady Ibraham, Executive Vice President of Research & Development at Cytokinetics INC (NASDAQ:CYTK), recently sold 12,033 shares of the company's stock for a total of $747,850. These "sell-to-cover" transactions were mandated by the company to fulfill tax obligations linked to the vesting of Restricted Stock Units. Despite these sales, several financial firms have recently raised their price targets for Cytokinetics, citing positive developments in its drug programs.
Cytokinetics (CYTK) CEO receives new RSU and stock option awards
Cytokinetics President & CEO Robert I. Blum received an annual grant of 75,258 restricted stock units (RSUs) and stock options on March 15, 2026. The RSUs vest over three years, while the stock options, comprising 1,665 incentive and 111,864 non-qualified options with an exercise price of $60.06, vest in 48 equal monthly installments and expire in 2036. Following these awards, Blum's direct common stock holdings in Cytokinetics total 466,931 shares.
Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock
Sung Lee, EVP of Cytokinetics, sold 4,935 shares of CYTK stock for approximately $306,710, reducing his direct holding by 5.36%. This insider selling is part of a broader trend this week, with CEO Robert Blum and other senior executives also selling significant blocks of shares. Despite this, analysts largely maintain a "Moderate Buy" rating for Cytokinetics with an average target price of $89.89, even as the company missed EPS estimates but beat revenue expectations in its latest quarterly report.
Cytokinetics (CYTK) EVP executes 8,542-share sell-to-cover for RSU taxes
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 8,542 shares of common stock at $62.15 per share on March 17, 2026. This was a company-compelled "sell-to-cover" transaction to satisfy tax withholding obligations related to restricted stock unit vesting. Following these transactions, Callos directly holds 71,573 Cytokinetics shares, maintaining a significant equity stake.
Cytokinetics (CYTK) CFO share sale covers RSU tax obligations
Cytokinetics (CYTK) EVP and CFO Sung Lee sold 4,935 shares of common stock at $62.15 per share. This transaction was a company-compelled "sell-to-cover" to satisfy tax withholding obligations related to RSU vesting, not a discretionary sale. Following the sale, Lee still directly holds 87,127 shares, maintaining a substantial equity position in the company.
Cytokinetics Insiders Sold Shares Worth Over $3.6M
Cytokinetics insiders, including the President & CEO, EVP Research & Development, and EVP, Chief Commercial Officer, collectively sold over $3.6 million worth of company shares. These transactions, executed on March 17, 2026, were identified as company-compelled sell-to-cover actions to satisfy tax withholding obligations related to RSU vesting. After these sales, the insiders still retain significant direct and indirect ownership in the company.
[Form 4] CYTOKINETICS INC Insider Trading Activity
CYTOKINETICS INC's EVP of Research & Development, Fady Malik, reported the sale of 12,033 shares of common stock at $62.15 per share on March 17, 2026. These transactions were identified as "sell-to-cover" sales, compelled by the company to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). Following these sales, Malik directly holds 153,902 shares of CYTOKINETICS common stock, indicating that the transactions were tax-driven rather than discretionary.
Mizuho Raises Price Target for Cytokinetics (CYTK) to $100 | CYT
Mizuho has raised its price target for Cytokinetics (CYTK) to $100 from $84, maintaining an "Outperform" rating for the stock. This adjustment reflects a positive sentiment among various analysts, with several firms also recently increasing their price targets for CYTK. Cytokinetics, a biopharmaceutical company focused on muscle activators and inhibitors for debilitating diseases, is seen by analysts as having potential for growth, with an average target price of $92.00 from 17 analysts.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics, Incorporated announced inducement grants of stock options and restricted stock units (RSUs) to five new employees in accordance with Nasdaq Listing Rule 5635(c)(4). These grants, totaling 8,628 shares in stock options and 5,719 RSUs, were made on March 13, 2026, as a material inducement for their employment. The awards have specific vesting schedules and terms, aligning with the company's equity incentive plan.
Mizuho Boosts Cytokinetics (NASDAQ:CYTK) Price Target to $100.00
Mizuho has increased its price target for Cytokinetics (NASDAQ:CYTK) to $100 from $84, maintaining an "outperform" rating and implying a potential upside of approximately 59.8% from its current price. Despite missing EPS estimates, the biopharmaceutical company's revenue beat expectations, and analyst consensus remains a "Moderate Buy" with a target of $89.89. Insider selling activity has been noted, with approximately 95,622 shares sold over the last 90 days.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics, Incorporated announced inducement grants of stock options and restricted stock units (RSUs) to five new employees. These grants, totaling 8,628 shares of common stock options and 5,719 RSUs, were made on March 13, 2026, as a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The awards have specific vesting schedules, with options vesting over four years and RSUs over three years, subject to continued service.
New Aficamten HCM Data On Exercise Capacity And Flexibility Might Change The Case For Investing In Cytokinetics (CYTK)
Cytokinetics announced new data for MYQORZO (aficamten) from recent trials, highlighting improved exercise capacity and flexibility in treatment for hypertrophic cardiomyopathy patients. This data reinforces the drug's clinical profile, which is crucial as Cytokinetics focuses on its U.S. and EU launch execution. However, investors should also consider the ongoing risks associated with high cash burn and potential future dilution for the company.
Cytokinetics (CYTK) awards stock options and RSUs to chief legal officer
Cytokinetics Inc. (CYTK) recently granted significant equity awards to its Chief Legal & Admin Officer, Jeffrey Hessekiel, as detailed in an SEC Form 4 filing. On March 15, 2026, he received incentive and non-qualified stock options, along with restricted stock units, all subject to vesting conditions and continued employment. Following these transactions, Hessekiel directly holds 107,943 shares of Cytokinetics common stock.
Cytokinetics (CYTK) EVP awarded new stock options and RSUs
Cytokinetics (CYTK) EVP Andrew Callos was granted new equity awards, including incentive stock options, non-qualified stock options, and restricted stock units, as part of his compensation on March 15, 2026. These awards, totaling 1,665 incentive stock options, 29,480 non-qualified stock options with an exercise price of $60.06, and 33,966 restricted stock units, are subject to vesting schedules and his continued employment. Following these grants, Callos directly holds 81,824 shares of common stock, with no open-market purchases or sales reported in this SEC filing.
JPMorgan Chase & Co. Raises Cytokinetics (NASDAQ:CYTK) Price Target to $75.00
JPMorgan Chase & Co. has raised its price target for Cytokinetics (NASDAQ:CYTK) from $74.00 to $75.00, maintaining an "overweight" rating. This new target implies a potential upside of over 21% from the current stock price. Despite insider selling activity, the biopharmaceutical company holds a "Moderate Buy" consensus rating from analysts, with an average target price significantly higher than JPMorgan's, at $89.05.
JPMorgan Boosts Price Target on Cytokinetics (CYTK) Amid Positive Outlook
JPMorgan has raised its price target for Cytokinetics (CYTK) to $75 and maintained an Overweight rating, adding it to its Analyst Focus List due to its potential as a significant growth opportunity. This positive re-evaluation follows regulatory approval for Myqorzo, a treatment for obstructive hypertrophic cardiomyopathy, and the anticipation of future data releases which could further enhance its market success. Despite promising developments, Cytokinetics faces financial challenges including negative revenue growth, significant losses, and a distress zone Altman Z-Score.
Granahan Investment Management LLC Purchases Shares of 53,550 Cytokinetics, Incorporated $CYTK
Granahan Investment Management LLC recently acquired 53,550 shares of Cytokinetics, Inc. (NASDAQ:CYTK) for approximately $2.94 million in the third quarter. Other institutional investors have also adjusted their holdings, with several analysts maintaining "Buy" or "Outperform" ratings and setting price targets up to $136. Insiders, however, have sold a significant number of shares, while the company's stock trades at $60.83 with a market cap of $7.49 billion.
